Artiva Biotherapeutics (ARTV) vs Cabaletta Bio (CABA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Artiva Biotherapeutics (ARTV) has outperformed Cabaletta Bio (CABA) over the past year, gaining 141.4% versus a loss of 15.1%. Artiva Biotherapeutics is the larger company by market cap ($342.2 million vs $334.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | CABA |
|---|---|---|
| Share price | $7.00 | $1.97 |
| Market cap | $342.23M | $334.00M |
| 1-day change | -3.71% | -2.48% |
| YTD return | +63.17% | -10.05% |
| 1-year return | +141.38% | -15.09% |
| 5-year return | — | -83.93% |
| EPS (TTM) | $-3.23 | $-1.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.53 | $4.23 |
| 52-week low | $2.71 | $1.83 |
| Distance from 52-week high | -51.82% | -53.43% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +411.43% | +572.59% |
| Average volume | 402.33K | 4.67M |
| Shares outstanding | 48.89M | 169.55M |
| Employees | 115 | 154 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARTV has outperformed CABA by 156.5 percentage points over the past year.
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 115 employees
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
ARTV vs CABA FAQ
Which is bigger, Artiva Biotherapeutics or Cabaletta Bio?
Artiva Biotherapeutics (ARTV) is larger, with a market capitalization of $342.23M compared with $334.00M for Cabaletta Bio (CABA).
Which stock has performed better over the past year, ARTV or CABA?
ARTV returned +141.38% over the past 12 months, compared with -15.09% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Artiva Biotherapeutics and Cabaletta Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.